Edition:
India

Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

12.90USD
1:30am IST
Change (% chg)

$-1.19 (-8.45%)
Prev Close
$14.09
Open
$14.31
Day's High
$14.31
Day's Low
$12.47
Volume
311,510
Avg. Vol
115,843
52-wk High
$23.49
52-wk Low
$10.24

Summary

Name Age Since Current Position

Lawrence Hineline

62 2019 Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary

Michael Halstead

46 2019 Executive Vice President, General Counsel and Secretary

Mark Neumann

56 2018 Executive Vice President, Chief Commercial Officer

Andrew Satlin

63 2017 Executive Vice President and Chief Medical Officer

Robert Davis

67 2015 Senior Vice President and Chief Scientific Officer

John Bardi

2019 Senior Vice President - Market Access, Policy and Government Affairs

Suresh Durgam

2018 Senior Vice President, Late Stage Clinical Development and Medical Affairs

Michael Olchaskey

2018 Senior Vice President, Head of Regulatory Affairs

Kimberly Vanover

52 2014 Senior Vice President, Early Stage Clinical Development and Translational Medicines

Robert Van Nostrand

62 2017 Lead Independent Director

Sharon Mates

66 2014 Chairman of the Board, President, Chief Executive Officer

Christopher Alafi

55 2014 Independent Director

Richard Lerner

80 2014 Independent Director

Joel Marcus

71 2014 Independent Director

Rory Riggs

66 2014 Independent Director

Biographies

Name Description

Lawrence Hineline

Mr. Lawrence J. Hineline CPA is the Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary of Intra-Cellular Therapies, Inc. Mr. Hineline has served as Senior Vice President of Finance of the Company since January 2019 and Chief Financial Officer and Treasurer of the Company since the Merger in August 2013. He also served as Vice President of Finance of the Company from the Merger in August 2013 to December 2018. He has served as Vice President of Finance, Chief Financial Officer and Secretary of ITI since June 2002. Mr. Hineline also served as the Secretary of the Company from August 2013 until September 2014. From December 2000 to November 2003, Mr. Hineline was the Vice President of Finance and Chief Financial Officer of Functional Genetics, Inc. Prior to that, Mr. Hineline served as the Vice President of Finance of North American Vaccine, Inc. and its predecessor companies from 1993 to 2000, and he served as Corporate Controller from 1989 to 1993. During this time, Mr. Hineline oversaw the growth of the accounting function and its systems for the company that emerged as a start-up and was later acquired by Baxter Health Care. Mr. Hineline is a licensed CPA in the State of Maryland and received his Bachelor’s Degree from the University of Maryland Baltimore County.

Michael Halstead

Mr. Michael I. Halstead is the Executive Vice President, General Counsel and Secretary of Intra-Cellular Therapies, Inc. He has served as Executive Vice President of the Company since January 2019, General Counsel of the Company since July 2014 and Secretary of the Company since September 2014. He also served as Senior Vice President of the Company from July 2014 to December 2018. From July 2005 until December 2013, Mr. Halstead served in a number of leadership positions at Warner Chilcott plc. Most recently he was Senior Vice President, Corporate Development at Warner Chilcott where he directed the company’s corporate development, legal and human resources functions. Prior to that, Mr. Halstead was an attorney at the firm of Davis Polk & Wardwell. Mr. Halstead received his bachelor’s degree from Boston University and his Juris Doctor degree from Villanova University School of Law.

Mark Neumann

Mr. Mark Neumann is Executive Vice President, Chief Commercial Officer of the Company. Mr. Neumann has served as Executive Vice President, Chief Commercial Officer of the Company since October 2018. From June 2014 to October 2018, Mr. Neumann served in leadership positions at Amgen, most recently serving as Vice President, Global Marketing. Before Amgen, from February 2014 to June 2014 Mr. Neumann served in a leadership position at AstraZeneca. Before joining AstraZeneca, from June 1988 to February 2014, he served at Bristol Myers Squibb Company in positions of increasing responsibility, including commercial leadership roles. Mr. Neumann is a licensed CPA (inactive) and received his bachelor’s degree from Lafayette College.

Andrew Satlin

Mr. Andrew Satlin M.D. is the Executive Vice President and Chief Medical Officer of Intra-Cellular Therapies, Inc. Dr. Satlin has served as Executive Vice President and Chief Medical Officer of the Company since November 2017. From July 2008 to November 2017, Dr. Satlin served in a number of leadership positions at Eisai, Inc., most recently serving as Executive Vice President, Global Head of Medicine Creation Strategy, Neurology Business Group. Before joining Eisai, from 1997 to 2008, he served at Novartis in positions of increasing responsibility, including leadership of the Neurosciences regulatory group. Prior to joining Novartis, Dr. Satlin was an Assistant Professor of Psychiatry at Harvard Medical School. Dr. Satlin was also the Director of Geriatric Psychiatry and established a dementia clinic at McLean Hospital in Massachusetts. Dr. Satlin received his medical degree from Harvard Medical School and completed his residency in psychiatry and fellowship in geriatric psychiatry at McLean Hospital. Dr. Satlin received his Bachelor’s Degree from Yale University.

Robert Davis

Mr. Robert E. Davis is Ph.D., is the Senior Vice President and Chief Scientific Officer of Intra-Cellular Therapies, Inc. Mr Davis previously served as President and CEO of 3-D Pharmaceutical Consultants, providing consulting services to the Company from December 2005 to November 2015. From December 2000 until November 2005, Dr. Davis served as the Executive Vice President, Research and Development at ACADIA Pharmaceuticals. From January 1994 until October 2000, Dr. Davis held various positions at MitoKor, a development stage biotechnology company focused on the design and development of drug therapies for mitochondrial diseases, serving at various times as its President, Chief Executive Officer and Chief Scientific Officer. Earlier, Dr. Davis held various positions at Parke-Davis Pharmaceutical Research, Warner-Lambert. Earlier in his career, he participated in the discovery and development of Cognex, the first drug approved for treating Alzheimer’s disease, Neurontin, the first drug approved for treating neuropathic pain, and Nuplazid, a potential new treatment for psychosis associated with Parkinson disease. Dr. Davis received his B.S., M.S and Ph.D in Psychobiology from the University of Illinois.

John Bardi

Mr. John A. Bardi Senior Vice President - Market Access, Policy and Government Affairs of the company. Mr. Bardi joins ITCI from Otsuka America Pharmaceuticals, Inc where he was initially recruited as Vice President, Market Access, Policy Advocacy, and Government Affairs to build and establish new functions and capabilities to support their products including Abilify®, Abilify Maintena® and Rexulti®. Most recently Mr. Bardi led the Payer & Integrated Delivery Networks Business Development efforts in support of the launch of the first FDA approved Digital Medicine Product. Prior to Otsuka, Mr. Bardi spent 7 years at Bristol-Myers Squibb (BMS) where he served as one of the original members of the US Abilify® Marketing team leading the Payer, Pricing and Advocacy function. In his final years at BMS, Mr. Bardi was Vice President for Market Access leading the function and field based teams in support of BMS' full portfolio of products including Neuroscience, Cardiology, and Oncology. John received his Bachelor of Arts in Public Administration from West Chester University of Pennsylvania and his Masters in Health Services Administration from The George Washington University in Washington, DC.

Suresh Durgam

Dr. Suresh Durgam M.D. is Senior Vice President, Late Stage Clinical Development and Medical Affairs of the Company. Dr. Durgam, brings over 15 years of experience in neuropsychiatric drug development, including the development of antipsychotics and antidepressants. Dr. Durgam most recently served in clinical development leadership roles at Allergan plc where he was the clinical lead responsible for development of treatments for mood disorders including rapid-acting antidepressant programs. Dr. Durgam was also the clinical development lead of the antipsychotic, cariprazine, advancing the compound from Phase I to approval in schizophrenia and bipolar disorder. Dr. Durgam graduated with his medical degree from the Siddhartha Medical College in India and received his residency training in psychiatry at Scott & White Clinic and Hospital – Texas A&M University System College of Medicine.

Michael Olchaskey

Dr. Michael Olchaskey Pharm.D. is Senior Vice President, Head of Regulatory Affairs of the Company. Dr. Olchaskey received his Bachelor of Science in Pharmacy and Doctor of Pharmacy degree from Rutgers University. He also did a Post-Doctoral Fellowship jointly sponsored by Hoffmann La Roche and Rutgers University. Dr. Olchaskey has held positions of increasing responsibility and scope in Regulatory Affairs at Allergan plc over the last 16 years. He has overseen a wide array of submissions and approvals for products, including cariprazine, asenapine, escitalopram, levomilnacipran, milnacipran, and vilazodone.

Kimberly Vanover

Dr. Kimberly E. Vanover Ph.D. is the Senior Vice President, Early Stage Clinical Development and Translational Medicines of Intra-Cellular Therapies, Inc. Dr. Vanover joined ITI in March 2007 and has been Vice President, Clinical Development of ITI since January 2011. Previously, she was Executive Director, Clinical Development of ITI from January 2008 to December 2010 and Senior Director, Clinical Development of ITI from March 2007 to December 2007. She has spent over 20 years on the discovery and development of small molecule drugs for the treatment of neuropsychiatric and neurodegenerative diseases. Dr. Vanover was Postdoctoral Research Scientist at Lederle Laboratories from 1992 to 1994, Postdoctoral Research Trainee in the Department of Psychiatry at the University of California San Diego from 1994 to 1995, Senior Scientist and Group Leader at CoCensys from 1995 to 2000 and held positions as Group Leader and Director at ACADIA Pharmaceuticals from 2000 to 2007. In these positions, Dr. Vanover participated in the discovery and development of a broad range of new CNS therapeutics, including drugs to treat psychosis, insomnia, cognitive impairment, movement disorders, acute and neuropathic pain, anxiety, epilepsy, and drug abuse. Dr. Vanover received her B.A. in Psychology from the University of Missouri and her Ph.D. in Biopsychology from the University of Chicago.

Robert Van Nostrand

Mr. Robert L. Van Nostrand is the Lead Independent Director of Intra-Cellular Therapies, Inc. He has served on our board of directors since January 2014. Mr. Van Nostrand has been a self-employed advisor and investor since 2010, as well as a member of various public and private company boards of directors. Mr. Van Nostrand was Executive Vice President and Chief Financial Officer of Aureon Biosciences, Inc., a private pathology life science company, from January 2010 to July 2010. Prior to joining Aureon Biosciences, Mr. Van Nostrand served as Executive Vice President and Chief Financial Officer of AGI Dermatics, Inc., a private biotechnology company, from July 2007 to September 2008 when the company was acquired. From May 2005 to July 2007, Mr. Van Nostrand served as the Senior Vice President and Chief Compliance Officer of OSI Pharmaceuticals, Inc., then a publicly-traded biotechnology company, where he previously served as Vice President and Chief Financial Officer from December 1996 through May 2005 and as Vice President, Finance and Administration prior to that. He also served as OSI’s Treasurer from March 1992 to May 2005 and Secretary from March 1995 to January 2004. Mr. Van Nostrand joined OSI as Controller and Chief Accounting Officer in September 1986. Prior to joining OSI, Mr. Van Nostrand served in a managerial position with the accounting firm, Touche Ross & Co., currently Deloitte. Mr. Van Nostrand serves as chairman of the board of directors of Yield10 Bioscience, Inc., a publicly-traded agricultural bioscience company, as well as chairman of its audit committee and a member of its compensation committee. Mr. Van Nostrand also serves on the board of directors of Achillion Pharmaceuticals, Inc., a publicly-traded biotechnology company, where he serves as chairman of the audit committee and a member of the compensation committee.

Sharon Mates

Dr. Sharon Mates Ph.D. is the Chairman of the Board, President, Chief Executive Officer of Intra-Cellular Therapies, Inc. Dr. Mates has been Chairman, President and Chief Executive Officer of the Company since the Merger in August 2013 and has been the Chairman of the board of directors, President and Chief Executive Officer of ITI since June 2002. Dr. Mates co-founded ITI in May 2002. Prior to co-founding ITI, Dr. Mates was a co-founder of Functional Genetics, and served as its Chairman and Chief Executive Officer from December 2000 until August 2003. From 1989 to 1998, Dr. Mates was the President and a board member of North American Vaccine Inc. and its predecessor companies. Dr. Mates serves on the board of the Biotechnology Innovation Organization (BIO), emerging companies section. Dr. Mates has also served on the Advisory Council of the Center for Society and Health at the Harvard School of Public Health, the Board of Visitors of the Biotechnology Institute of the University of Maryland and the board of directors of Gilda’s Club of New York. Earlier in her career, Dr. Mates spent several years as a research analyst and investment banker, and as an advisor to the life sciences industry. Dr. Mates received her B.S. from the Ohio State University and her Ph.D. from the University of Washington, and completed her postdoctoral fellowships at The Massachusetts General Hospital and Harvard Medical School.

Christopher Alafi

Dr. Christopher D. Alafi Ph.D. is an Independent Director of Intra-Cellular Therapies, Inc. Dr. Alafi became a director of the Company following the Merger that occurred in August 2013 and has served on the board of directors of ITI since January 2013. Dr. Alafi has been a General Partner of Alafi Capital Company, LLC, a venture capital firm and a principal stockholder of the Company, since 1995. He was previously a Physiology and Anatomy teacher at Santa Monica College, a visiting scholar in the Department of Chemistry at Stanford University and a researcher at DNAX. Dr. Alafi previously served as a director of ISTO Technologies, Coley Pharmaceutical Group, Inc., CyberGold, Inc. and Stereotaxis, Inc. Dr. Alafi received a B.A. in Biology from Pomona College and a D.Phil. in Biochemistry from the University of Oxford.

Richard Lerner

Dr. Richard A. Lerner M.D. is an Independent Director of Intra-Cellular Therapies, Inc. Dr. Lerner became a director of the Company following the Merger that occurred in August 2013 and has served on the board of directors of ITI since 2002. Dr. Lerner served as President of the Scripps Research Institute, a private, non-profit biomedical research organization from 1986 to January 2012, and since then has served and continues to serve as Institute Professor. Dr. Lerner received the Wolf Prize in Chemistry in 1994, the California Scientist of the Year Award in 1996, the Paul Ehrlich and Ludwig Darmstaedter Prize in 2003, and the Prince of Asturias Award in 2012 for his achievements in the development of catalytic antibodies and combinatorial antibody libraries. Dr. Lerner is a member of the National Academy of Sciences and the Royal Swedish Academy of Sciences. Dr. Lerner previously served as a director of Kraft Foods, Inc. and Teva Pharmaceutical Industries Ltd. and currently serves as a director of Opko Health, Inc., Zebra Biologics, Cognos Therapeutics and Interex, Inc. Dr. Lerner received his M.D. from Stanford Medical School.

Joel Marcus

Mr. Joel S. Marcus J.D., CPA is an Independent Director of Intra-Cellular Therapies, Inc. Mr. Marcus became a director of the Company following the Merger that occurred in August 2013 and has served on the board of directors of ITI since April 2006. Mr. Marcus is the Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), or Alexandria, an urban office REIT focused on world-class collaborative life science and technology campuses in AAA innovation cluster locations. Mr. Marcus co-founded Alexandria in 1994 with a business plan and $19 million in seed capital and has led its growth into an S&P 500 company. Alexandria has a significant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. In 1996, Mr. Marcus also founded Alexandria Venture Investments, the company’s strategic venture capital arm. Prior to co-founding Alexandria, Mr. Marcus had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions, with expertise in the biopharmaceutical industry. He was also a practicing certified public accountant and tax manager with Arthur Young & Co., where he focused on the financing and taxation of REITs. Mr. Marcus was one of the original architects and co-founders of Accelerator Corporation and AgTech Accelerator, for which he serves on the board of directors. He also serves on the boards of Applied Therapeutics Inc., Boragen, Inc., Frequency Therapeutics, MeiraGTx Holdings plc and Yumanity Therapeutics. Mr. Marcus previously served as a director of Atara Biotherapeutics, Inc. Mr. Marcus is a recipient of the Ernst & Young Entrepreneur of the Year Award (Los Angeles—Real Estate). He was awarded his undergraduate and Juris Doctor degrees at the University of California, Los Angeles.

Rory Riggs

Mr. Rory B. Riggs is an Independent Director of Intra-Cellular Therapies, Inc. Mr. Riggs has served on our board of directors since January 2014. He is co-founder and chairman of Royalty Pharma, the largest acquiror of drug royalties, and Cibus Global Ltd, the leading company in gene editing in agriculture. In addition, he sits on the following other boards of directors: FibroGen, Inc., Nuredis, Inc., GeneNews, Ltd. and eReceivables, LLC (Chair). Since June 2006, Mr. Riggs also serves as Managing Member of New Ventures, a venture fund focused on biotechnology and healthcare. Since 2010, Mr. Riggs serves as founder and Chief Executive Officer of Locus Analytics, LLC, a data analytics company that organizes and analyzes financial and economic data using a new class of information system. Locus is the parent of Syntax Indices, which has contracted with major index providers to provide diversified variants of their major benchmarks, such as S&P 500, MSCI EAFE and the Wilshire 5000. Mr. Riggs served as the President of Biomatrix, Inc., a biomedical company, from 1996 until 2000. From 1991 to 1995, he was Chief Executive Officer of RF&P Corporation, an investment company owned by the Virginia Retirement System. He was also Managing Director of PaineWebber and Company, a stock brokerage and asset management firm, in the mergers and acquisitions field. Mr. Riggs holds a B.A. from Middlebury College and an M.B.A. from Columbia University.

Basic Compensation